We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after December 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CAPSID-FREE AAV VECTORS, COMPOSITIONS, AND METHODS FOR VECTOR PRODUCTION AND GENE DELIVERY
PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND THEIR USE
BACULOVIRUS SYSTEM FOR THE EXPRESSION OF A GENE THERAPY VECTOR
DYRK1 INHIBITORS AND USES THEREOF
DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT
SCALABLE LENTIVIRAL VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS
METHODS FOR DIAGNOSIS AND THERAPEUTIC FOLLOW UP OF MUSCULAR DYSTROPHIES
TREATMENT OF MIGRAINE HEADACHES, IN PARTICULAR CLUSTER HEADACHES
1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF
Compositions and methods for duchenne muscular dystrophy gene therapy
WIDESPREAD GENE DELIVERY OF GENE THERAPY VECTORS
Method for the inactivation of virginiamycin
COMPOSITIONS AND METHODS FOR DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY
METHOD FOR DIAGNOSING MUSCULAR DYSTROPHY
Treatment of an inflammation of the tarsal gland of the eyelid